HiSiaddi is an innovative foreign trade service provider driven by both technology transformation and export business. We have established a "1+2+3+4=1" service system and can supply D-chiro-Inositol sourced from multiple well-known original manufacturers. As a foreign trader with independent R&D capabilities, HiSiaddi has collaborated with factories on technology conversion and accurately captured market demands, repeatedly solving customized production requirements for D-chiro-Inositol clients. Below is a case of HiSiaddi delivering customized D-chiro-Inositol solutions.
Contact HiSiaddi customer service for more customized service inquiries.
The purchaser is CALMORA, a leading mid-to-high-end dietary supplement group on the US West Coast. Its products are sold nationwide at Whole Foods Market and CVS Pharmacy chains, focusing on PCOS regulation and fertility-support endocrine capsules. All raw materials comply with US USP, FDA GRAS and cGMP standards. The group has an annual rigid demand of 42 tons of D-chiro-Inositol (DCI). Rejecting standard domestic off-the-shelf materials, the brand put forward four stringent customized technical indicators, which failed to be fulfilled by multiple domestic raw material manufacturers before entrusting HiSiaddi to deliver the full customization and production process. Mandatory customized parameters from the client:
1. Purity Customization: HPLC assay content ≥99.6%, D-type chiral purity >99.7%, total isomer impurities of inositol ≤0.2% (conventional commercial materials only reach 98.5%~99.0%).
2. Powder Physical Property Customization: Particle size concentrated in 80–120 mesh, powder flowability ≥22s/100g; no bridging or shell adhesion during high-speed capsule filling.
3. Process Route Customization: Restricted to full bioconversion technology; chemical hydrolysis and pesticide precursor (kasugamycin / D-pinitol) routes are prohibited to meet US Clean Label labeling requirements.
4. Internal Control Safety Customization: Heavy metals Pb/As/Cd <0.1ppm, organic solvents ND (not detected); complete English COA and third-party USDA-recognized test reports to be provided.
The client previously contacted 4 top domestic DCI manufacturers, yet all attempts stalled due to incompatible production capacity:
1. Most manufacturers mass-produce materials via D-pinitol hydrolysis for low costs, but their production routes fail to meet the client’s solvent-free and Clean Label requirements and cannot be modified.
2. A small number of bioconversion factories can only stably achieve 99.2% purity, lacking supporting production lines for refined crystallization and particle size classification. Mixed coarse and fine powder caused frequent machine blockages and material waste during the client’s lab-scale capsule filling trials.
3. Manufacturers only supply standardized ready-made goods and refuse to invest separately in crystallization technical upgrades and dedicated third-party testing. Quotations for customized sample batches surged by over 45% with a minimum order threshold of 5 tons, while the client only required a small batch of 800kg for new product trial production, resulting in a total mismatch between supply and demand.
HiSiaddi screened specialized manufacturers equipped with pilot bioconversion workshops, avoiding traditional chemical hydrolysis production lines, and coordinated dedicated customized crystallization sections at partner factories:
· Optimized concentration and low-temperature recrystallization processes with vacuum drying at a controlled temperature of 45–55°C, extended resin desalination procedures to remove trace isomer impurities, stabilizing finished product purity within the range of 99.65%–99.72%.
· Installed graded air flow screening equipment to precisely lock the particle size range of 80–120 mesh and strictly control the proportion of fine powder and coarse particles to meet powder flowability indicators.
1. Small Sample Phase (3 batches of 50g each): Adjust crystallization parameters across three batches, with English test reports sent simultaneously for US laboratory testing of chirality, impurities and dissolution rate.
2. Pilot Scale Phase (25kg): Full production following mass production processes for the client’s capsule filling pilot, resolving caking issues during high-speed filling.
3. Trial Production Batch (800kg): Finalized customized grade DCI-CAL01 with fixed complete process parameters and locked mass production standards.
A full set of documents tailored to US import regulations: GRAS process statements, production flow files, dual CNAS and US third-party inspection reports, English SDS, and free sales certificates. Food-grade aluminum foil composite inner bags and outer barrels printed with exclusive brand shipping marks are adopted to avoid US customs label non-compliance risks.
1. Initial Shipment: 800kg customized DCI shipped from Shanghai Port to Los Angeles with zero customs clearance abnormalities. The capsule filling pass rate increased from 76% with standard materials to 99.8%, enabling official shelf placement of finished products at CVS Pharmacies.
2. Long-Term Annual Contract Signed: After the customized grade was finalized, the total annual demand of 42 tons is delivered in 6 monthly batches. Factories reserve dedicated customized production lines exclusively for HiSiaddi orders without mixing standard bulk raw materials.
3. Extended Supporting Services: The client subsequently entrusted HiSiaddi with customized compound raw materials for its new Myo+DCI blended powder product line.
1. Industry Pain Points: Major domestic D-chiro-Inositol manufacturers focus on mass-produced standard off-the-shelf goods, with scarce high-purity customized bioconversion production lines. Separate technical transformation incurs high costs, making factories reluctant to accept small-batch personalized customization.
2. Logic of Mid-to-High-End Overseas Brands: Nutraceuticals sold at European and American pharmacies are restricted by labeling regulations and filling production lines. Purity, crystal form, particle size and production source are all tied to product filings; standard raw materials easily lead to failed new product registration and finished product scrapping.
3. HiSiaddi Value: Connecting R&D, production and compliance ends, coordinating dedicated technical upgrades and phased sampling verification at factories. As a third-party foreign trade service provider, we balance customization costs and factory production scheduling to realize personalized production of niche high-end raw materials.
Contact HiSiaddi customer service for more customized service inquiries.
+86-13120989737 
info@hisiaddi.com 
English
